Clinical efficacy of delayed-release dimethyl fumarate in Asian patients with relapsing-remitting multiple sclerosis: integrated analysis of define and confirm

Clinical efficacy of delayed-release dimethyl fumarate in Hispanic patients with relapsing-remitting multiple sclerosis: integrated analysis of define and confirm

Journal of the Neurological Sciences ◽

10.1016/j.jns.2015.08.1078 ◽

2015 ◽

Vol 357 ◽

pp. e306

Author(s):

L. Hernandez ◽

R.J. Fox ◽

R. Gold ◽

J.T. Phillips ◽

M. Okwuokeny ◽

...

Keyword(s):

Multiple Sclerosis ◽

Clinical Efficacy ◽

Dimethyl Fumarate ◽

Integrated Analysis ◽

Delayed Release ◽

Relapsing Remitting ◽

Hispanic Patients ◽

Efficacy and Tolerability of Delayed-release Dimethyl Fumarate in Black, Hispanic, and Asian Patients with Relapsing-Remitting Multiple Sclerosis: Post Hoc Integrated Analysis of DEFINE and CONFIRM

Neurology and Therapy ◽

10.1007/s40120-017-0077-5 ◽

2017 ◽

Vol 6 (2) ◽

pp. 175-187 ◽

Cited By ~ 6

Author(s):

Robert J. Fox ◽

Ralf Gold ◽

J. Theodore Phillips ◽

Macaulay Okwuokenye ◽

Annie Zhang ◽

...

Keyword(s):

Multiple Sclerosis ◽

Dimethyl Fumarate ◽

Integrated Analysis ◽

Delayed Release ◽

Asian Patients ◽

Relapsing Remitting ◽

Post Hoc ◽

Efficacy of Delayed-release Dimethyl Fumarate in Newly Diagnosed Patients With Relapsing-Remitting Multiple Sclerosis: Eight-Year Follow-up of an Integrated Analysis of DEFINE, CONFIRM, and ENDORSE

10.26226/morressier.59a3eda8d462b8028d895222 ◽

2017 ◽

Cited By ~ 1

Author(s):

Ralf Gold

Keyword(s):

Multiple Sclerosis ◽

Dimethyl Fumarate ◽

Integrated Analysis ◽

Newly Diagnosed ◽

Delayed Release ◽

Relapsing Remitting ◽

Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM

Clinical Therapeutics ◽

10.1016/j.clinthera.2017.06.012 ◽

2017 ◽

Vol 39 (8) ◽

pp. 1671-1679 ◽

Cited By ~ 17

Author(s):

Óscar Fernández ◽

Gavin Giovannoni ◽

Robert J. Fox ◽

Ralf Gold ◽

J. Theodore Phillips ◽

...

Keyword(s):

Multiple Sclerosis ◽

Dimethyl Fumarate ◽

Integrated Analysis ◽

Efficacy And Safety ◽

Delayed Release ◽

Relapsing Remitting ◽

Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies

European Journal of Neurology ◽

10.1111/ene.13272 ◽

2017 ◽

Vol 24 (5) ◽

pp. 726-733 ◽

Cited By ~ 28

Author(s):

E. Havrdova ◽

G. Giovannoni ◽

R. Gold ◽

R. J. Fox ◽

L. Kappos ◽

...

Keyword(s):

Multiple Sclerosis ◽

Disease Activity ◽

Dimethyl Fumarate ◽

Phase Iii ◽

Integrated Analysis ◽

Delayed Release ◽

Relapsing Remitting ◽

Efficacy of delayed‐release dimethyl fumarate in relapsing‐remitting multiple sclerosis: integrated analysis of the phase 3 trials

Annals of Clinical and Translational Neurology ◽

10.1002/acn3.148 ◽

2014 ◽

Vol 2 (2) ◽

pp. 103-118 ◽

Cited By ~ 38

Author(s):

Vissia Viglietta ◽

David Miller ◽

Amit Bar‐Or ◽

J. Theodore Phillips ◽

Douglas L. Arnold ◽

...

Keyword(s):

Multiple Sclerosis ◽

Dimethyl Fumarate ◽

Integrated Analysis ◽

Phase 3 ◽

Delayed Release ◽

Relapsing Remitting ◽

Delayed-release Dimethyl Fumarate Demonstrated No Difference in Clinical Outcomes versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Real-world EFFECT Study

10.26226/morressier.59a3e8b6d462b8028d8951f5 ◽

2017 ◽

Cited By ~ 1

Author(s):

Jacob Sloane

Keyword(s):

Multiple Sclerosis ◽

Clinical Outcomes ◽

Real World ◽

Dimethyl Fumarate ◽

Effect Study ◽

The Real ◽

Delayed Release ◽

Relapsing Remitting ◽

Corrigendum to “Safety and Efficacy of Delayed-Release Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: 9 Years’ Follow-up of DEFINE, CONFIRM, and ENDORSE”

Therapeutic Advances in Neurological Disorders ◽

10.1177/1756286420968357 ◽

2020 ◽

Vol 13 ◽

pp. 175628642096835

Keyword(s):

Multiple Sclerosis ◽

Dimethyl Fumarate ◽

Safety And Efficacy ◽

Delayed Release ◽

Relapsing Remitting ◽

Incidence and mitigation of gastrointestinal events in patients with relapsing–remitting multiple sclerosis receiving delayed-release dimethyl fumarate: a German phase IV study (TOLERATE)

Therapeutic Advances in Neurological Disorders ◽

10.1177/1756286418768775 ◽

2018 ◽

Vol 11 ◽

pp. 175628641876877 ◽

Cited By ~ 9

Author(s):

Ralf Gold ◽

Eugen Schlegel ◽

Birte Elias-Hamp ◽

Christian Albert ◽

Stephan Schmidt ◽

...

Keyword(s):

Multiple Sclerosis ◽

Dimethyl Fumarate ◽

Delayed Release ◽

Gastrointestinal Events ◽

Relapsing Remitting ◽

Relapsing Remitting Multiple Sclerosis ◽

Phase Iv

Comparative Effectiveness Using A Matching-Adjusted Indirect Comparison Between Delayed-Release Dimethyl Fumarate and Fingolimod for The Treatment of Relapsing-Remitting Multiple Sclerosis

Value in Health ◽

10.1016/j.jval.2015.09.2902 ◽

2015 ◽

Vol 18 (7) ◽

pp. A750 ◽

Cited By ~ 3

Author(s):

RJ Fox ◽

G Cutter ◽

A Chan ◽

J Xiao ◽

M Okwuokenye ◽

...

Keyword(s):

Multiple Sclerosis ◽

Comparative Effectiveness ◽

Indirect Comparison ◽

Dimethyl Fumarate ◽

Delayed Release ◽

Relapsing Remitting ◽

Adjusted Indirect Comparison ◽